Advertisement
Home Tags Respiratory Problems: Misc.

Tag: Respiratory Problems: Misc.

Fluticasone Furoate Slows Loss of Lung Function in COPD

0
Alone or in combination, reduces rate of FEV1 decline in those with moderate COPD and high risk of CVD

July 2017 Briefing – Pulmonology

0
Here are what the editors at HealthDay consider to be the most important developments in Pulmonology for July 2017. This roundup includes the latest...
For patients with acute respiratory distress syndrome

Conservative Fluid Management Benefits Black ARDS Patients

0
Improved one-year mortality for non-Hispanic black acute respiratory distress syndrome patients
From 1991 to 2005

Benefit of Newer NICU Ventilation Strategies Questioned

0
No significant decline seen in oxygen dependence at 36 weeks or improvement in lung function at age 8
Rescue workers and survivors of the 9/11 terrorist attacks on the World Trade Center seem to have an increased risk for heart and lung diseases years later

Risk of Heart, Respiratory Disease Up in 9/11 Survivors

0
Intense exposure on first day of disaster tied to substantially increased risk of future disease

June 2017 Briefing – Pulmonology

0
Here are what the editors at HealthDay consider to be the most important developments in Pulmonology for June 2017. This roundup includes the latest...
The traditional idiopathic pulmonary fibrosis algorithm performs poorly

Idiopathic Pulmonary Fibrosis Algorithm Performs Poorly

0
Positive predictive value and sensitivity of 42.2 and 55.6 percent; modified IPF algorithm improves PPV
Most patients with active uveitis of unknown origin with abnormal chest radiographs have findings consistent with sarcoidosis

Abnormal Chest Radiograph in Active Uveitis Often Sarcoidosis

0
Fifteen percent of patients with active uveitis of unknown origin have abnormal chest radiographs

May 2017 Briefing – Pulmonology

0
Here are what the editors at HealthDay consider to be the most important developments in Pulmonology for May 2017. This roundup includes the latest...
Mepolizumab is associated with significantly more weeks in remission than placebo among patients with eosinophilic granulomatosis with polyangiitis

Remission Up for Mepolizumab in Eosinophilic Granulomatosis

0
Significantly more weeks of accrued remission for mepolizumab treatment versus placebo